In this context, the development novel FN3K inhibitors in combination with current chemotherapeutic molecules as nanoformulations may deliver selectivity and specificity in promoting the formation of glycated Nrf2 for treating several Nrf2-mediated cancers. The gene discussed is NFE2L2; the disease is cancer.